hotspot -WSS

hotspot

author：leisure time 2025-08-19 15:02:12 - browse：1144

Adam's take main illustration — Molly Ferguson/STAT

Hello! Some takes and thoughts on Gilead’s Trodelvy troubles, Elevation Oncology’s surprising rise, and Kura Oncology’s “wall-crossing” stock sale.

Gilead needs Arcellx more than ever

The clinical trial setback for Trodelvy in non-small cell lung cancer reported by Gilead Sciences on Monday was another dose of bad news for the company’s oncology business. Strategically, does it make sense for Gilead to invest even more in antibody-drug conjugates like Trodelvy, where its lackluster profile and increased competition overall makes winning seem unlikely? Or, should Gilead double down on its Kite division and CAR-T cell therapy — the type of cancer treatments where it truly excels?

If the answers to those questions are no and yes (I lean that way), then Gilead’s current partnership with Arcellx, which is developing a BCMA-targeted CAR-T therapy for multiple myeloma, becomes a lot more important.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Biogen walks away from Aduhelm, years after polarizing approval

WSS

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

Biogen walks away from Aduhelm, years after polarizing approval

ASCO Takeaways: Winners, snoozers, and the art of cancer care

For pregnant people, addiction treatment shouldn't mean a call to child protective services

How generative AI ratchets up security threats for health systems

A new initiative will help leaders fight the next pandemic

entertainment

hotspot

Gilead needs Arcellx more than ever

hotspot

Drug repurposing or repositioning? The language matters

Investment in vaccine development is lagging, report finds

Jerome Adams on the need for new antivirals for Covid

Medicare Advantage insurers face 0.2% cut to 2025 payments

Medical records are filled with copy

Biogen walks away from Aduhelm, years after polarizing approval

At least 13 dead in Texas as scorching temps continue

Medicare drug price negotiation legal challenge met with skepticism

United colonoscopy coverage change 'may cost lives,' doctors say

FTC loses bid to block Novant's North Carolina hospital merger

focus

Bernie Sanders is gearing up to subpoena pharma CEOs

An outdated Medicare rule harms dementia patients with anxiety

BD to buy Edwards patient monitoring unit for $4.2 billion

An outdated Medicare rule harms dementia patients with anxiety

Anthony Fauci pushes back on GOP claims during Covid hearing

White House pharmacy plagued with problems, investigation finds

focus

focus

leisure time

knowledge